摘要
目的探讨依达拉奉治疗急性脑梗死患者的疗效及对血清基质金属蛋白酶9(matrix metalloproteinase-9,MMP-9)蛋白表达的影响。方法选择发病24h内的急性脑梗死患者50例,按照随机数字表法分为对照组和治疗组(各25例)。两组患者视病情轻重及并发症给予对症治疗,其中治疗组联合应用依达拉奉30mg静脉滴注,2次/d,疗程14天。采用Western blot测定两组患者治疗前及治疗后第3天、第7天血清基质金属蛋白酶9蛋白表达,观察两组患者治疗前及治疗后第14天时临床神经功能缺损程度评分。结果治疗组治疗后第3、7天血清MMP-9蛋白表达与对照组比较差异有统计学意义(t3d=10.231,t7d=25.212,P<0.01)。治疗组患者治疗后14天时神经功能缺损评分明显低于对照组(t=3.077,P<0.05)。结论依达拉奉改善急性脑梗死患者神经功能的作用,可能与其降低血清中MMP-9蛋白水平有关。
Objective To observe the curative effects of edaravone in treating patients with acute cerebral infarction and its affect on the expression of serum matrix metalloproteinase-9 （MMP-9）. Methods Fifty patients with acute cerebral infarction within 24 hours of onset were randomly and equally divided into treatment group （25 cases） and control group （25 cases）. All patients were given routine treatment. Treatment group were further administrated with intravenous drip of 30 mg Edaravone, twice a day, total of 14 days. The expression of serum MMP-9 was investigated by Western blot method before treatment and on the 3rd and 7th day of treatment. The scores measured by neurological functional deficit scale were compared before treatment and on the 14th day of treatment in the two groups. Results The expression of serum MMP-9 in the treatment group on the 3rd and 7th day of treatment was significantly lower than that in the control group （t3d=10.231,t7d=25.212,P0.01）. The score of neurological functional deficit in the treatment group （13.57±7.24） was significantly lower than that in the control group （18.07±8.23） （t=3.077,P0.01）. Conclusion Edaravone can improve the nervous function in patients with acute cerebral infarction probably through down regulation of serum MMP-9 expression.
出处
《华南国防医学杂志》
CAS
2011年第1期16-18,共3页
Military Medical Journal of South China
关键词
脑梗死
基质金属蛋白酶9
依达拉奉
Cerebral infarction
Matrix metalloproteinase-9
Edaravone
